Author(s): YU Yongfei, ZHANG Li, JIA Fumin, WEI Heng, RUAN Qingyuan, SONG Lin, YIN Hongxiang, ZHOU Rui, XU Kang
Pages: 244-245,280
Year: 2014 Issue:  4
Journal: Journal of Internal Intensive Medicine
Keyword:  Recombinant tissue-type plasminogen activator; Acute cerebral infarction; Thrombolysis; Ozagrel Sodium;
Abstract: 目的:探讨重组组织型纤溶酶原激活剂(rt-PA)静脉溶栓治疗急性脑梗死(ACI)患者的疗效及安全性.方法:将发病在4.5h内ACI患者139例,且均符合静脉溶栓适应证,按入院顺序分为rt-PA组(61例)和对照组(ACI)(78例),分别给予rt-PA静脉溶栓和奥扎格雷钠治疗.采用NIHSS及mRS评分比较2组患者治疗后24 h、7d、90 d的疗效及安全性.结果:rt-PA组治疗后7d,NIHSS评分较对照组改善更显著.rt-PA组90 d mRS评分优于对照组.2组病死率、症状性颅内出血发生率无统计学差异.结论:ACI患者4.5h内给予rt-PA静脉溶栓,疗效优于奥扎格雷钠,且较为安全.